The evERA Phase 3 RCT delivers the strongest efficacy signal yet for an oral SERD in the post-CDK4/6 inhibitor setting — but the absence of overall survival data is the single fact that will determine whether this approval translates into commercial reality. A 44% reduction in risk of progression or death in the ITT population and a 62% reduction in the ESR1-mutated subgroup, both measured against standard endocrine therapy plus everolimus — an active, guideline-recognized comparator, not a placebo arm — represent a more demanding evidentiary standard than prior SERD monotherapy trials. Median PFS of 8.8 months (ITT) and 10.0 months (ESR1-mutated) in the giredestrant arm, published in the New England Journal of Medicine, constitute Phase 3 RCT evidence at the highest tier. The closest mechanistic peer is elacestrant, an approved oral SERD in the ESR1-mutated post-CDK4/6 inhibitor population, though elacestrant was studied as monotherapy against endocrine monotherapy — a structurally weaker comparator — making cross-trial PFS benchmarking unreliable. No precedent clears both the mechanistic and contextual fit bar for the full giredestrant-plus-everolimus combination in this exact population: elacestrant covers the oral SERD mechanism but not the combination context; BOLERO-2 covers the everolimus backbone but in a CDK4/6 inhibitor-naïve population with a different endocrine partner. [1] Payer precedent is unambiguous in its warning: elacestrant's US cost-effectiveness analysis produced an ICER of approximately $2,900,560 per QALY in the ESR1-mutated population — far exceeding the $150,000 per QALY willingness-to-pay threshold — and the evERA combination adds everolimus costs on top of giredestrant, compressing the cost-effectiveness profile further. [2] HTA bodies including NICE, CADTH, and the G-BA have consistently penalized PFS-only submissions in this indication. The sharpest risk is not regulatory rejection but reimbursement restriction: approval without OS data in a setting where payers have already demonstrated they will not reimburse at list price. [3]
Phase 3 RCT evidence (highest tier) with significant PFS benefit against an active comparator, but no OS data reported and payer precedent — elacestrant ICER of $2,900,560/QALY in ESR1-mutated patients — signals severe cost-effectiveness challenge for the combination. [2]
| Indication | ER-positive, HER2-negative locally advanced or metastatic breast cancer who had disease progression or recurrence following treatment with a CDK4/6 inhibitor and endocrine therapy |
| Drug | Giredestrant |
| Mechanism of Action | Oral selective oestrogen receptor degrader (SERD), full antagonist |
| Company | Roche |
| Trial Phase | Phase III |
| Trial Acronym | evERA Breast Cancer |
| NCT ID | NCT05306340 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Oncology |
| Publication Journal | The New England Journal of Medicine |
| Comparator Arm | Standard endocrine therapy plus everolimus |
| Primary Endpoint | Investigator-assessed progression-free survival in the intention-to-treat and ESR1-mutated populations |
| Hazard Ratio (ESR1-mutated) | 0.38 (95% CI: 0.27-0.54, p<0.001) |
| Hazard Ratio (ITT) | 0.56 (95% CI: 0.44-0.71, p<0.001) |
| Median PFS (ESR1-mutated, Giredestrant + Everolimus) | 10.0 months |
| Median PFS (ITT, Giredestrant + Everolimus) | 8.8 months |
| Regulatory Agency | US Food and Drug Administration (FDA) |
| PDUFA Date (Advanced Breast Cancer) | 18 December 2026 |
| PDUFA Date (Early-Stage Breast Cancer) | 30 November 2026 |
Roche's Giredestrant Combination Improves PFS in Advanced Breast Cancer
Roche announced detailed results from the Phase III evERA Breast Cancer study, published in The New England Journal of Medicine, showing its investigational drug giredestrant combined with everolimus significantly improved progression-free survival (PFS) in ER-positive, locally advanced or metastatic breast cancer patients previously treated with a CDK4/6 inhibitor and endocrine therapy. The combination reduced the risk of disease progression or death by 44% in the intent-to-treat (ITT) population and 62% in the ESR1-mutated population compared to standard endocrine therapy plus everolimus. Median PFS was 8.8 months (ITT) and 10.0 months (ESR1-mutated) for the giredestrant arm. The FDA has set PDUFA goal dates of December 18, 2026, for advanced disease and November 30, 2026, for early-stage breast cancer.
- The evERA trial demonstrated a significant improvement in progression-free survival (PFS) for patients with ESR1-mutated ER-positive advanced breast cancer. The giredestrant plus everolimus arm achieved a median PFS of 10.0 months, a substantial increase compared to 5.5 months in the comparator arm (standard endocrine therapy plus everolimus). This translated to a stratified hazard ratio of 0.38 (95% CI: 0.27-0.54, p<0.001), indicating a 62% reduction in the risk of disease progression or death in this specific patient subgroup.
- In the broader intent-to-treat population, giredestrant in combination with everolimus also showed a statistically significant improvement in PFS. Patients treated with the giredestrant combination experienced a median PFS of 8.8 months, compared to 5.5 months for those on the comparator regimen. This represents a 44% reduction in the risk of disease progression or death, with a hazard ratio of 0.56 (95% CI: 0.44-0.71, p<0.001), highlighting the broad benefit across the study population.
- The safety profile of the giredestrant combination was manageable and consistent with the known safety profiles of the individual medicines, with no unexpected safety findings such as photopsia and low rates of bradycardia. While overall survival (OS) data were immature at the time of analysis, a clear positive trend was observed in both the ITT (HR=0.69) and ESR1-mutated populations (HR=0.62), suggesting potential long-term benefits that will be further evaluated in ongoing follow-up analyses.
- Based on the evERA data, the US FDA accepted Roche’s New Drug Application (NDA) for giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer, setting a PDUFA goal date of December 18, 2026. Additionally, an NDA for giredestrant as an adjuvant treatment in early-stage breast cancer (based on lidERA results) was accepted under Priority Review, with a PDUFA date of November 30, 2026, underscoring giredestrant's potential across multiple treatment settings.
Addressing Unmet Needs in Post-CDK4/6i ER+ Advanced Breast Cancer
Therapeutic resistance following CDK4/6 inhibitor plus endocrine therapy remains a central unmet need in HR+/HER2− metastatic breast cancer, driving a shift toward molecularly selected, combination-based strategies in the post-progression setting. Multiple resistance mechanisms — including ESR1 mutations, PI3K/AKT/mTOR pathway activation, RB1 loss, and FGFR alterations — can co-occur and substantially reduce sensitivity to endocrine monotherapy alone, underscoring the need for precision-guided sequencing.
ESR1-mutated tumors: Acquired ESR1 mutations, which emerge under endocrine therapy pressure and are often subclonal and dynamic, represent a key resistance mechanism and a validated therapeutic target. Elacestrant demonstrated improved progression-free survival versus standard-of-care endocrine therapy in ESR1-mutated ER+/HER2− metastatic breast cancer in the phase 3 EMERALD trial, earning FDA and EMA approval. The PFS benefit was particularly pronounced in patients with prior CDK4/6 inhibitor exposure of at least 12 months (median PFS 8.6 versus 1.9 months; HR 0.41; 95% CI 0.26–0.63). Proactive ctDNA monitoring strategies, evaluated in SERENA-6 and PADA-1, have demonstrated that detecting emergent ESR1 mutations before radiographic progression can extend endocrine-based disease control by approximately 5 to 7 months.
PIK3CA/AKT1/PTEN-altered tumors: Activation of the PI3K/AKT/mTOR pathway — through PIK3CA mutation, AKT1 mutation, or PTEN loss — is an established resistance mechanism and a biomarker-defined population for targeted intervention. Capivasertib plus fulvestrant demonstrated significant PFS improvement in patients with PIK3CA/AKT1/PTEN-altered tumors in the phase 3 CAPItello-291 trial, with consistent benefit observed across global, Japanese, and Chinese subgroups. PTEN loss, occurring in approximately 5% of HR+/HER2− metastatic breast cancer patients, is now recognized alongside PIK3CA and AKT1 as a predictive biomarker for capivasertib. In PIK3CA-mutated patients with early relapse, inavolisib plus palbociclib and fulvestrant achieved both progression-free and overall survival improvement in the INAVO120 trial.
Patients with co-occurring or complex resistance profiles: Comprehensive genomic profiling has revealed that resistance mechanisms such as ESR1 mutations and PI3K pathway alterations frequently co-occur, complicating treatment selection. Endocrine monotherapy has shown limited efficacy in the acquired resistance setting, and multiple randomized studies support combination regimens — pairing targeted agents with endocrine therapy — as the preferred post-CDK4/6i strategy, except in carefully selected patients with low disease burden, indolent biology, or frailty where tolerability is a major concern.
Patients with FGFR alterations: FGFR alterations represent an emerging resistance mechanism identified through next-generation sequencing-guided genomic profiling in the post-CDK4/6i setting. Unlike ESR1 and PI3K pathway alterations, FGFR alterations remain investigational targets, with ongoing trials evaluating selective FGFR inhibitors in this population.
Broader oral SERD development beyond elacestrant: Beyond elacestrant, multiple oral SERDs — including camizestrant, giredestrant, imlunestrant, and amcenestrant — are under investigation to address the limitations of fulvestrant and expand options for ESR1-mutated and broader ER+ post-CDK4/6i populations. In the phase 2 SERENA-2 trial, camizestrant improved PFS as second-line treatment, while trials of giredestrant and amcenestrant failed to show PFS benefit in the second-line metastatic setting, highlighting that efficacy within this drug class is not uniform.
evERA Trial Design and Key Outcomes in Advanced ER+ Breast Cancer
Several randomized and real-world studies have evaluated treatment strategies for ER-positive, HER2-negative advanced breast cancer following progression on CDK4/6 inhibitor-based therapy, spanning oral SERDs, continued CDK4/6 inhibition with switched endocrine therapy, mTOR inhibition, and single-agent elacestrant. The evidence base is heterogeneous in design and population, but collectively highlights ESR1 mutation status and prior therapy exposure as key determinants of outcome.
| Trial / Study | Design | Population | Key Interventions | Primary Endpoint | Key Results |
|---|---|---|---|---|---|
| Oral SERDs Meta-analysis (6 RCTs; N=2,808) | PRISMA 2020–compliant systematic review and meta-analysis of phase II–III RCTs; random effects models | HR+/HER2− advanced breast cancer after prior endocrine therapy | Oral SERDs vs. standard endocrine therapy | Progression-free survival (PFS) | PFS HR 0.79 (95% CI 0.70–0.89); ORR OR 1.67 (95% CI 1.23–2.28; ~21% vs. ~14%); OS HR 0.72 (95% CI 0.57–0.90); PFS benefit concentrated in ESR1-mutated tumors (HR 0.57; 95% CI 0.48–0.67); no significant PFS advantage in ESR1 wild-type disease |
| Elacestrant Real-World Study (GuardantINFORM; N=756) | Retrospective, real-world database study linking sequencing and claims data; Kaplan-Meier and Cox regression | ESR1-mutant metastatic breast cancer; 76% with prior CDK4/6 inhibitor, 38% prior chemotherapy | Elacestrant monotherapy | Time-to-treatment-discontinuation (TTD) | Median TTNT 6.4 months; TTD 4.6 months; TTNT 8.8 months in ≤1 prior metastatic lines vs. 6.0 months in third-line; ESR1 polyclonality (≥4 alterations) associated with shorter TTNT of 5.2 months (HR 1.44; 95% CI 1.01–2.06); dual ESR1 + PI3K-pathway mutations associated with median TTNT of 5.2 months |
| Dalpiciclib + ET Phase II Trial (NCT05613270) | Prospective, single-center, single-arm phase II; [¹⁸F]FES PET/CT–guided patient selection | HR+/HER2− advanced breast cancer progressed on prior CDK4/6 inhibitor; ≥1 [¹⁸F]FES-positive lesion; N=40 planned | Dalpiciclib + physician-selected endocrine therapy | PFS | Secondary endpoints: ORR, DCR, OS; trial ongoing |
| Everolimus Post-Palbociclib (N=41) | Retrospective, 2-institute review; January 2015–March 2018 | HR+/HER2− metastatic breast cancer progressed on palbociclib; 83% had ≥3 prior chemotherapy or hormonal therapies; 61% visceral disease | Everolimus-based therapy | Median PFS | Median PFS 4.2 months (95% CI 3.2–6.2); median OS 18.7 months (95% CI 9.5 to not reached); ORR and CBR both 17.1% |
Giredestrant's Expanding Clinical Program and Future Outlook
Giredestrant's clinical development extends well beyond the second-line ER+/HER2− metastatic setting, with active investigation across early-stage and HER2-positive disease contexts. The trials below reflect a broad combinatorial strategy, pairing giredestrant with CDK4/6 inhibitors, HER2-targeted agents, and evaluating it as a neoadjuvant monotherapy comparator.
| Indication | Trial | Phase | Intervention Model |
|---|---|---|---|
| ER+, HER2−, untreated early breast cancer (neoadjuvant) | coopERA Breast Cancer (NCT04436744) | Phase 2 | Open-label, randomised, controlled; giredestrant 30 mg oral daily vs. anastrozole 1 mg oral daily (2-week window-of-opportunity phase), followed by 16-week neoadjuvant phase with palbociclib 125 mg oral daily added to each arm |
| HER2+, ER+ locally advanced or metastatic breast cancer (previously untreated, maintenance) | heredERA Breast Cancer (NCT05296798) | Phase 3 | Randomised, open-label, two-arm; induction with fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) plus a taxane, followed by 1:1 randomisation to maintenance giredestrant plus PH FDC SC vs. PH FDC SC (plus optional endocrine therapy) |
The knowledge base does not have sufficient information on this aspect.
Giredestrant: A New Horizon for Post-CDK4/6i ER+ Breast Cancer
The detailed results from the Phase III evERA Breast Cancer study mark a pivotal moment for patients battling ER-positive, HER2-negative metastatic breast cancer, especially those whose disease has progressed after prior CDK4/6 inhibitor and endocrine therapy. This patient population represents a significant unmet need, often facing limited effective treatment options. Giredestrant, an investigational next-generation oral selective estrogen receptor degrader (SERD), in combination with everolimus, demonstrated a substantial improvement in progression-free survival, reducing the risk of disease progression or death by 44% overall and an impressive 62% in patients with ESR1 mutations.
This robust efficacy in ESR1-mutated tumors is particularly noteworthy. ESR1 mutations are a well-established driver of endocrine resistance, making effective treatments for this subgroup highly sought after. The data strongly supports the utility of giredestrant in overcoming this critical resistance mechanism. This also underscores the growing importance of ESR1 mutation testing as a predictive biomarker, guiding clinicians toward more personalized and effective treatment strategies.
However, the evolving landscape of oral SERDs presents a dynamic competitive environment. With other agents like elacestrant also demonstrating efficacy in ESR1-mutated disease, giredestrant will need to carve out a distinct position. While giredestrant monotherapy has shown a tolerable safety profile in earlier studies, the combination with everolimus introduces the known adverse event profile of everolimus, which will be a key consideration for patient tolerability and adherence in this heavily pre-treated population. Furthermore, while the evERA results are compelling, the prior Phase II acelERA study showed only a trend toward benefit in ESR1-mutated patients, suggesting that careful patient selection and further biomarker refinement may be crucial for maximizing giredestrant's impact. As PDUFA dates approach, giredestrant stands poised to offer a new and much-needed therapeutic option, potentially reshaping the treatment algorithm for advanced ER+ breast cancer.
Frequently Asked Questions
References
- [1] Lloyd MR, Weipert CM et al.. Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026 Jan 6. 41201834
- [2] Dhakal A, Antony Thomas R et al.. Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast cancer : basic and clinical research. 2020. 32753876
- [3] Nerone M, Rossi L et al.. Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies. Cancers. 2023 Jun 23. 37444415
- [4] Saji S, Taira N et al.. Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. The Lancet. Oncology. 2022 May. 35405087
- [5] Herrera-Abreu MT, Guan J et al.. Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer. Nature communications. 2024 Nov 5. 39500869
- [6] Guarneri V, Giorgi CA et al.. Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial. European journal of cancer (Oxford, England : 1990). 2021 Sep. 34225066
- [7] Tokunaga E, Iwata H et al.. Capivasertib and fulvestrant for patients with HR-positive/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast cancer (Tokyo, Japan). 2025 Jan. 39379782
- [8] Sahin TK, Aksoy S et al.. Oral selective estrogen receptor degraders (SERDs) in hormone receptor-positive HER2-negative metastatic breast cancer after progression with CDK4/6 inhibitors. Expert review of anticancer therapy. 2025 May. 40082241
- [9] Fusco N, Guerini-Rocco E et al.. Immunohistochemistry for PTEN testing in HR +/HER2- metastatic breast cancer. Virchows Archiv : an international journal of pathology. 2025 Oct. 40931235
- [10] Garcia-Fructuoso I, Gomez-Bravo R et al.. Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment. Current opinion in oncology. 2022 Nov 1. 36000362
- [11] Sledge GW Jr, Toi M et al.. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA oncology. 2020 Jan 1. 31563959
- [12] Sudo K, Nishimura R et al.. Treatment and Reasons for Choosing Treatment in Breast Cancer Patients Who Underwent Next-Generation Sequencing Test. Oncology. 2025. 39904323
- [13] Pérez-Tenorio G, Alkhori L et al.. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Jun 15. 17575221
- [14] Al-Shamsi HO, Abdelwahed N et al.. Post-CDK4/6 Inhibitor Therapeutic Approaches in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Current Evidence and Emerging Strategies-A Narrative Review. Diagnostics (Basel, Switzerland). 2026 Jun 10. 42351448
- [15] Gheysen M, Punie K et al.. Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review. Cancer treatment reviews. 2024 Nov. 39293125
- [16] Liang J, Ingalla ER et al.. Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer. Science translational medicine. 2022 Sep 21. 36130016
- [17] Liu L, Graff SL et al.. Genomic and clinicopathological characteristics of low oncotype recurrent score breast cancers with subsequent metastasis. Histopathology. 2026 Jun. 41664643
- [18] Kuemmel S, Harper-Wynne C et al.. heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC cancer. 2024 May 24. 38789924
- [19] Yao R, Qu Y et al.. Rationale and Trial Design of DAWNA-FES Trial: Single-Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [(18)F]FES PET/CT in Patients With HR+/HER2- Advanced Breast Cancer. Cancer innovation. 2026 Jun. 42078117
- [20] Fusco N, Malapelle U. ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer. The journal of liquid biopsy. 2026 Sep. 42437171
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
